Karyopharm Therapeutics | KPTI - Loan Capital


Karyopharm Therapeutics reported $278.22M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Abbott USD 9.9B 1.7B Dec/2025
Amgen USD 50B 2.43B Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
BioCryst Pharmaceuticals USD 428.67M 234.31M Dec/2025
Bristol-Myers Squibb USD 42.85B 1.62B Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Enanta Pharmaceuticals USD 0 0 Dec/2024
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Incyte USD 30.2M 5.17M Dec/2025
J&J USD 39.44B 30M Dec/2025
Karyopharm Therapeutics USD 278.22M 278.22M Dec/2025
MacroGenics USD 70M 256K Dec/2025
Merck USD 39.97B 6B Sep/2025
Nektar Therapeutics USD 63.16M 44.35M Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
Pfizer USD 57.41B 93M Sep/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sangamo BioSciences USD 0 0 Jun/2022
Takeda JPY 4.27T 81.29B Dec/2025
Tectonic Therapeutic USD 43K 57K Dec/2025
TG Therapeutics USD 245.64M 305K Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
Xencor USD 76.48M 11.29M Dec/2025